BNP Paribas Exane analyst Navann Ty upgraded Phibro Animal Health (PAHC) to Neutral from Underperform with a $24 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health Corp’s Earnings Call Highlights Robust Growth
- Phibro Animal Health Reports Strong Q3 Results
- Phibro Animal Health price target raised to $21 from $20 at Morgan Stanley
- Phibro Animal Health: Balancing Strong EPS Growth with Cautious Hold Rating Amidst Flat Animal Health Performance
- Phibro Animal Health reports Q3 adjusted EPS 63c, consensus 52c